Table 1.
Clinical characteristics of patients with AIH
| Country | Patients, n | Type 1 AIH | Male:female | Age at onset, years | Ref. |
|---|---|---|---|---|---|
| East Asia | |||||
| Japan | 1,056 | 93.8%a | 1:6.0 | 59.9±14.7 | [16] |
| Taiwan | 48 | 100%b | 1:3.4 | 59.8±14.2, 58.5 (21–84) | [23] |
| Korea | 343 | 97.4% | 1:7.3 | 52.8 (19–87) | [24] |
| China | 173 | ≥90.2%c | 1:6.8 | 53 (18–74) | [25] |
| Southeast Asia | |||||
| Singapore | 24 | 91.7%d | 1:11 | Mean: 57, median: 63 | [21] |
| Brunei Darussalam | 19 | 100%b | 1:3.75 | 52 (33–70) | [22] |
| Thailand | 50 | n.a. | 1:6.1 | 62 (29–85) | [40] |
| South Asia | |||||
| India | 125 | 71.2% | 1:1.8 | 45.45±16.15; 46 (8–79) | [26] |
| Pakistan | 58 | 62.0% | 1:1.5 | 14.5 (4–70) | [27] |
| Europe and North America | |||||
| Denmark | 1,721 | n.a. | 1:2.6 | Incidence peak: around 70 | [17] |
| UK | 245 | ≥73.9%c | 1:5.0 | 56.1 (2.5–87) | [29] |
| Italy | 163 | 76.7% | 1:4.6 | 36±21e | [30] |
| Canada | 125 | ≥72.0%c | 1:3.1 | 43.5±16.6 | [31] |
a
Estimated data based on the text; ANA positive (89.1%: 886/994), ANA negative and ASMA positive (4.7%: 47/994).
b
In this study, all AIH patients were diagnosed as having type 1 AIH.
c
Estimated data based on the text concerning ANA-positive patients. Although the number of ANA-negative and ASMA-positive patients was not described, they may increase the rate.
d
Estimated data based on the text; ANA and/or ASMA positive (91.7%: 22/24). The remaining 2 patients who tested negative for ANA and SMA were also anti-LKM negative.
e
Type 1 AIH (125 patients): 42 ± 20 years, and type 2 AIH (38 patients): 15 ± 10 years.